Brodalumab for treatment of immune checkpoint inhibitor-induced adverse events
This technology repurposes the FDA-approved anti-IL-17RA monoclonal antibody Brodalumab for the treatment of immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy.
Unmet Need: Targeted treatment for immune checkpoint inhibitor-associated toxicities
Current management of immune-related adverse events relies largely on corticosteroids and broad immunosuppressive therapies that can compromise anti-tumor immunity, increase infection risk, and limit continued immunotherapy treatment. As immune checkpoint inhibitors become standard of care across multiple cancer types, there is a growing need for more targeted approaches to control irAEs while maintaining cancer-fighting immune activity.
The Technology: IL-17 inhibition to treat immunotherapy-associated toxicities
This technology repurposes Brodalumab, an FDA-approved anti-IL-17 receptor A monoclonal antibody, for the treatment of immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy. By inhibiting IL-17-mediated inflammation, Brodalumab provides a targeted approach to reducing inflammatory toxicities while preserving anti-tumor immune responses. Potential applications include treatment of checkpoint inhibitor-induced colitis, dermatitis, arthritis, pneumonitis, and other inflammatory complications.
Applications:
- Management of immune checkpoint inhibitor-induced colitis
- Management of immune checkpoint inhibitor-induced dermatitis and psoriasis-like toxicities
- Management of immune checkpoint inhibitor-induced arthritis and inflammatory complications
- Steroid-sparing treatment for immune-related adverse events (irAEs)
- Enabling continuation of life-saving cancer immunotherapy
- Potential combination strategy with PD-1, PD-L1, and CTLA-4 inhibitors
Advantages:
- Targets IL-17-driven inflammation associated with multiple irAEs
- May preserves anti-tumor immunity compared to broad immunosuppressive therapies
- Utilizes an FDA-approved drug with established manufacturing, pharmacology, and safety data
- Enables accelerated clinical development through drug repurposing
- May reduce corticosteroid use and associated toxicities
- Applicable across multiple immune checkpoint inhibitor-treated cancers
Lead Inventor:
Patent Information:
Patent Pending(US20260015428)
Related Publications:
Tech Ventures Reference:
IR CU23267
Licensing Contact: Cynthia Lang